Effect of idelalisib/rituximab combination treatment of relapsed cll on the bcr signaling-related chemokines ccl3 and ccl4: Data from a phase 3, randomized, double-blind, placebo-controlled trial Meeting Abstract

   


Authors: Ghia, P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; Hallek, M. J.; Coiffier, B.; O'Brien, S. M.; Stilgenbauer, S.; Jiang, W.; Jahn, T. M.; Wong, M.; Lazarov, M.; Sharman, J. P.
Abstract Title: Effect of idelalisib/rituximab combination treatment of relapsed cll on the bcr signaling-related chemokines ccl3 and ccl4: Data from a phase 3, randomized, double-blind, placebo-controlled trial
Meeting Title: 19th Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 99
Issue: Suppl. 1
Meeting Dates: 2014 Jun 12-15
Meeting Location: Milan, Italy
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2014-06-01
Start Page: 56
End Page: 57
Language: English
ACCESSION: WOS:000342830900140
PROVIDER: wos
PMCID: PMC4060398
Notes: Meeting Abstract: P239 -- 19th Congress of the European-Hematology-Association -- JUN 12-15, 2014 -- Milan, ITALY -- Source: Wos